Lyra Therapeutics, Inc. (LYRA): Nasdaq/NYSE listing notice — Lyra Therapeutics receives Nasdaq deficiency notice for equity below $2.5M minimum

Lyra Therapeutics, Inc.

Stockholders' equity as of June 30, 2025 was ~$1.6M, below the $2.5M continued listing requirement.
Company has 45 calendar days (until October 4, 2025) to submit a plan to regain compliance to Nasdaq.
If plan is accepted, Nasdaq may grant up to 180 additional calendar days to evidence compliance.
Failure to regain compliance could lead to delisting; Company may appeal to a Nasdaq Hearings Panel.
No immediate effect on listing or trading of common stock under symbol LYRA on Nasdaq Capital Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Lyra Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

August 20, 2025, Lyra Therapeutics, Inc. (the “Company”) received a letter (the “Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on its Form 10-Q, the Company’s stockholders’ equity as of June 30, 2025 was approxim

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-186437

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.